Phase 1 Sleep Clinical Trials
25 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 25 trials
Recruiting
Phase 1Phase 2
Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia
Hypoxia, BrainBlood PressureStroke+5 more
University of Calgary12 enrolled1 locationNCT03255408
Recruiting
Phase 1Phase 2
Atomoxetine and DAW2022 on OSA Severity
Obstructive Sleep Apnea
Brigham and Women's Hospital18 enrolled1 locationNCT05350215
Recruiting
Phase 1Phase 2
Mindfulness Meditation for Insomnia
InsomniaMindfulnessTelemedicine+2 more
Brigham and Women's Hospital30 enrolled1 locationNCT06972303
Recruiting
Phase 1
Vascular Endothelial Dysfunction in Sleep Apnea
Obstructive Sleep Apnea of Adult
Columbia University110 enrolled1 locationNCT05289063
Recruiting
Phase 1Phase 2
Low-Tech Treatments for Obstructive Sleep Apnea
Traumatic Brain Injury (TBI)Obstructive Sleep Apnea (OSA)
Uniformed Services University of the Health Sciences60 enrolled1 locationNCT07301710
Recruiting
Phase 1
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
SleepHealthy Participants
Johns Hopkins University20 enrolled1 locationNCT07224074
Recruiting
Phase 1
A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
Excessive Daytime Sleepiness
Centessa Pharmaceuticals (UK) Limited208 enrolled3 locationsNCT07082829
Recruiting
Phase 1Phase 2
Project SHINE (Sleep Health INitiative for Equity): Culturally Informing a Sleep Extension Intervention for African American Adults
ObesityInsufficient Sleep
University of Minnesota90 enrolled1 locationNCT06226077
Recruiting
Phase 1Phase 2
Intermittent Hypoxia-initiated Plasticity in Humans: A Multi-pronged Therapeutic Approach to Treat Sleep Apnea and Overlapping Co-morbidities
Obstructive Sleep Apnea
VA Office of Research and Development60 enrolled1 locationNCT05558501
Recruiting
Phase 1Phase 2
DRonabinol Treatment of OSA
Obstructive Sleep Apnea
VA Office of Research and Development120 enrolled1 locationNCT06477952
Recruiting
Phase 1
Use of Passive Myofunctional Appliances for Snoring and Mild Obstructive Sleep Apnea
Sleep Apnea, Obstructive
University of Alberta40 enrolled1 locationNCT05497180
Recruiting
Phase 1Phase 2
Sleep Disordered Breathing With Opioid Use
Opioid UseSleep Apnea
VA Office of Research and Development150 enrolled1 locationNCT05589753
Recruiting
Phase 1
Exploring the Use of Phototherapy to Improve CPAP Compliance
Obstructive Sleep Apnea
University of Alberta30 enrolled1 locationNCT06960161
Recruiting
Phase 1
Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine
Sleep ApneaSleep Apnea, Obstructive
Vivek Jain40 enrolled1 locationNCT03860233
Recruiting
Phase 1Phase 2
Trazodone on OSA Endotypes
Obstructive Sleep Apnea
Brigham and Women's Hospital18 enrolled1 locationNCT06286189
Recruiting
Phase 1
Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?
Obstructive Sleep ApneaAlzheimer DiseaseSleep Apnea+1 more
University of California, San Diego260 enrolled1 locationNCT05094271
Recruiting
Phase 1
Affect of Duavive on Mood & Anxiety Symptoms
MenopauseDepression, AnxietySleep+1 more
St. Joseph's Healthcare Hamilton30 enrolled1 locationNCT04478305
Recruiting
Phase 1Phase 2
Rescue Pharmacotherapy for OSA
Obstructive Sleep Apnea
Brigham and Women's Hospital70 enrolled1 locationNCT05293600
Recruiting
Phase 1Phase 2
Pharmacological Activation of HMN for OSA Aim 2
Obstructive Sleep Apnea
Brigham and Women's Hospital16 enrolled1 locationNCT03858751
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of N-acetyl-5-methoxytryptamine prolonged release tablet against the innovator N-acetyl-5-methoxytryptamine prolonged release tablet conducted under fed conditions in healthy male and female volunteers.
N-acetyl-5-methoxytryptamine is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Zenith Technology Corporation Limited28 enrolled1 locationACTRN12622000966796